Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: The limited knowledge of the molecular alterations that characterize poorly differentiated neuroendocrine carcinomas has limited the clinical development of targeted agents directed to driver mutations. Here we aim to identify new molecular targets in colon neuroendocrine carcinomas (co-NEC) and proof the efficacy of matching drugs. Experimental Design: We performed a multi-omic analysis of co-NEC to identify genetic or epigenetic alterations that could be exploited as effective drug targets. We compared co-NEC samples with colorectal carcinomas (CRC) to identify neuroendocrine-specific traits. Patients with co-NEC and patient-derived xenografts were treated with a BRAFV600E-blocking drug to demonstrate sensitivity. Results: co-NEC and CRC are similar in their mutational repertoire, although co-NECs are particularly enriched in BRAFV600E mutations. We report for the first time that V600EBRAF-mutant co-NECs may benefit from BRAF inhibition in monotherapy and how EGFR status is essential to predict innate sensitivity and acquired resistance by a differential methylation of its gene regulatory regions. Conclusions: The identification of V600E BRAF mutations in high-grade co-NECs has allowed the description of radiological responses to combination therapy of BRAF and MEK inhibitors in basket clinical trials. However, the molecular rationale for this treatment combination was based on the presence of the BRAF mutation and the efficacy observed in other cancer types such as melanoma. Future drug development in this setting should test BRAF inhibitors upfront and the addition of anti-EGFR antibodies instead of MEK inhibitors for an efficient blockade of acquired resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224 · cited 1×
“Amore recent study also demonstrates that patients withmetastatic CRC benefit from a triple inhibition of EGFR, BRAF, andMEK in a phase III Beacon trial (13).”
BackgroundSelf-citation
Cited by
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“…melanoma and colon neuroendocrine carcinomas in which expression of EGFR (also known as HER1 or ERBB1 ) is epigenetically suppressed via promoter methylation 225,226 , high basal levels of EGFR in BRAF V600 - mutant CRC enable rapid reactivation of EGFR, RAS and CRAF upon BRAF inhibition 6,8 .”
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94
Exploring and bypassing resistance to targeted therapies in colorectal cancer
Favier, S., Xiong, W., Chalabi-Dchar, M., Chettab, K., Piercey, O., Wu, T., Fenouil, T., Albaret, M.-A., Jordheim, L. P., Diaz, J.-J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118741 · Cited by 12
Metadata
- Authors
- Capdevila, J., Arqués, O., Hernández Mora, J. R., Matito, J., Caratù, G., Mancuso, F. M., Landolfi, S., Barriuso, J., Jimenez-Fonseca, P., Lopez Lopez, C., Garcia-Carbonero, R., Hernando, J., Matos, I., Paolo, N., Hernández-Losa, J., Esteller, M., Martínez-Cardús, A., Tabernero, J., Vivancos, A., & Palmer, H. G.
- Venue
- Clinical Cancer Research
- Published
- 2020-02-14
- Volume
- 26
- Issue
- 4
- Pages
- 902-909
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2985970369
- Cited by
- 39
- References
- 2
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1266
- The paper
- Capdevila, J., Arqués, O., Hernández Mora, J. R., Matito, J., Caratù, G., Mancuso, F. M., Landolfi, S., Barriuso, J., Jimenez-Fonseca, P., Lopez Lopez, C., Garcia-Carbonero, R., Hernando, J., Matos, I., Paolo, N., Hernández-Losa, J., Esteller, M., Martínez-Cardús, A., Tabernero, J., Vivancos, A., & Palmer, H. G. (2020). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1266
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.